3.45BMarket Cap
LossP/E TTM
Key Figures
18.790Open
19.000High
2.72MVolume
LossP/E TTM
11.54P/E Dynamic
--Dividend TTM
1.46%Turnover Ratio
19.050Prev. Close
18.330Low
35.85MTurnover
LossP/E Static
3.56P/B
0.00%Div Yield TTM
-15.58%ROA
45.29752wk High
0.60Volume Ratio
-177.03MNet Profit
185.74MShares
-1.3544EPS TTM
0.36Beta
-25.20%ROE
16.24052wk Low
3.52%Amplitude
42.35%Gross Margin
3.45BMarket Cap
-7.54Reward/Risk
4.25%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Legend Biotech Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 22 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 55.78.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Legend Biotech Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Legend Biotech Corp Highlights
StrengthsRisks
Legend Biotech Corp News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
26
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Legend Biotech Corp Info
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Ticker SymbolLEGN
CompanyLegend Biotech Corp
CEOHuang (Ying)
Websitehttps://investors.legendbiotech.com/
Shareholders
FAQs
What is the current price of Legend Biotech Corp (LEGN)?
The current price of Legend Biotech Corp (LEGN) is 18.55.
What is the symbol of Legend Biotech Corp?
The ticker symbol of Legend Biotech Corp is LEGN.
What is the 52-week high of Legend Biotech Corp?
The 52-week high of Legend Biotech Corp is 45.30.
What is the 52-week low of Legend Biotech Corp?
The 52-week low of Legend Biotech Corp is 16.24.
What is the market capitalization of Legend Biotech Corp?
The market capitalization of Legend Biotech Corp is 3.45B.
Is Legend Biotech Corp (LEGN) currently rated as Buy, Hold, or Sell?
According to analysts, Legend Biotech Corp (LEGN) has an overall rating of Buy, with a price target of 55.78.
What is the Earnings Per Share (EPS TTM) of Legend Biotech Corp (LEGN)?
The Earnings Per Share (EPS TTM) of Legend Biotech Corp (LEGN) is -1.61.
